Found: 58
Select item for more details and to access through your institution.
DORAVIR: a French national survey of people with HIV-1 treated with an antiretroviral regimen including doravirine.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2024, v. 79, n. 8, p. 1974, doi. 10.1093/jac/dkae194
- By:
- Publication type:
- Article
Plasma concentrations of antiretroviral drugs in a successful 4-days-a-week maintenance treatment strategy in HIV-1 patients (ANRS 170-Quatuor trial).
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2024, v. 79, n. 6, p. 1380, doi. 10.1093/jac/dkae112
- By:
- Publication type:
- Article
Humoral response after accelerated schedule of HBV vaccination in MS patients before anti-CD20 therapy.
- Published in:
- Journal of Neurology, 2024, v. 271, n. 5, p. 2871, doi. 10.1007/s00415-023-12175-2
- By:
- Publication type:
- Article
High proportion of post-migration HIV acquisition in migrant men who have sex with men receiving HIV care in the Paris region, and associations with social disadvantage and sexual behaviours: results of the ANRS-MIE GANYMEDE study, France, 2021 to 2022.
- Published in:
- Eurosurveillance (15607917), 2024, v. 29, n. 11, p. 23, doi. 10.2807/1560-7917.ES.2024.29.11.2300445
- By:
- Publication type:
- Article
Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 Trial
- Published in:
- Clinical Infectious Diseases, 2023, v. 77, n. 7, p. 991, doi. 10.1093/cid/ciad297
- By:
- Publication type:
- Article
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2023, v. 78, n. 9, p. 2361, doi. 10.1093/jac/dkad247
- By:
- Publication type:
- Article
Four days/week antiretroviral maintenance strategy (ANRS 170 QUATUOR): substudies of reservoirs and ultrasensitive drug resistance.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2023, v. 78, n. 6, p. 1510, doi. 10.1093/jac/dkad119
- By:
- Publication type:
- Article
ANRS 174 DOXYVAC: AN OPEN-LABEL RANDOMIZED TRIAL TO PREVENT STIs IN MSM ON PrEP.
- Published in:
- Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 49
- By:
- Publication type:
- Article
IMPACT OF VACCINATION ON MPOX INCIDENCE IN MSM ON PrEP IN THE ANRS 174 DOXYVAC TRIAL.
- Published in:
- Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 86
- By:
- Publication type:
- Article
REMDESIVIR IN HOSPITALIZED COVID-19 PATIENTS: INDIVIDUAL PATIENT DATA META-ANALYSIS.
- Published in:
- Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 220
- By:
- Publication type:
- Article
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.
- Published in:
- Clinical Infectious Diseases, 2023, v. 76, n. 5, p. 861, doi. 10.1093/cid/ciac827
- By:
- Publication type:
- Article
Same-day initiation of bictegravir/emtricitabine/tenofovir alafenamide: Week 48 results of the FAST study—IMEA 055.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2023, v. 78, n. 3, p. 769, doi. 10.1093/jac/dkad008
- By:
- Publication type:
- Article
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial.
- Published in:
- Critical Care, 2023, v. 27, n. 1, p. 1, doi. 10.1186/s13054-022-04205-8
- By:
- Publication type:
- Article
Impact on renal function of daily and on-demand HIV pre-exposure prophylaxis in the ANRS-PREVENIR study.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2022, v. 77, n. 12, p. 3427, doi. 10.1093/jac/dkac336
- By:
- Publication type:
- Article
Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2022, v. 77, n. 7, p. 1980, doi. 10.1093/jac/dkac117
- By:
- Publication type:
- Article
Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among HIV-Negative Participants Using Tenofovir/Emtricitabine-Based Preexposure Prophylaxis in 2020: A Substudy of the French National Agency for Research on AIDS and Viral Hepatitis PREVENIR and Inserm SAPRIS-Sero Cohorts
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Increased risk of severe COVID-19 in hospitalized patients with SARS-CoV-2 Alpha variant infection: a multicentre matched cohort study.
- Published in:
- BMC Infectious Diseases, 2022, v. 22, n. 1, p. 1, doi. 10.1186/s12879-022-07508-x
- By:
- Publication type:
- Article
Impact of Anti PD-1 Immunotherapy on HIV Reservoir and Anti-Viral Immune Responses in People Living with HIV and Cancer.
- Published in:
- Cells (2073-4409), 2022, v. 11, n. 6, p. 1015, doi. 10.3390/cells11061015
- By:
- Publication type:
- Article
Household transmission of SARS-CoV-2 infection in the Paris/Ile-de-France area.
- Published in:
- European Journal of Clinical Microbiology & Infectious Diseases, 2022, v. 41, n. 3, p. 445, doi. 10.1007/s10096-021-04345-9
- By:
- Publication type:
- Article
Increased Production of B-Cell Activating Cytokines and Altered Peripheral B-Cell Subset Distribution during HIV-Related Classical Hodgkin Lymphoma.
- Published in:
- Cancers, 2022, v. 14, n. 1, p. 128, doi. 10.3390/cancers14010128
- By:
- Publication type:
- Article
HIV-1 RNA Kinetics in Blood Plasma and in Seminal Plasma of Men Starting a Dolutegravir-Based Triple-Combination Regimen at the Time of Primary HIV-1 Infection.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Mechanisms of HIV-1 evasion to the antiviral activity of chemokine CXCL12 indicate potential links with pathogenesis.
- Published in:
- PLoS Pathogens, 2021, v. 17, n. 4, p. 1, doi. 10.1371/journal.ppat.1009526
- By:
- Publication type:
- Article
Pharmacological data of a successful 4‐days‐a‐week regimen in HIV antiretroviral therapy (ANRS 162‐4D trial).
- Published in:
- British Journal of Clinical Pharmacology, 2021, v. 87, n. 4, p. 1930, doi. 10.1111/bcp.14586
- By:
- Publication type:
- Article
Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study-authors' response.
- Published in:
- 2020
- By:
- Publication type:
- letter
Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial).
- Published in:
- 2020
- By:
- Publication type:
- journal article
Addition of Maraviroc Versus Placebo to Standard Antiretroviral Therapy for Initial Treatment of Advanced HIV Infection: A Randomized Trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Propensity Score Analysis of Artesunate Versus Quinine for Severe Imported Plasmodium falciparum Malaria in France.
- Published in:
- Clinical Infectious Diseases, 2020, v. 70, n. 2, p. 280, doi. 10.1093/cid/ciz206
- By:
- Publication type:
- Article
Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?
- Published in:
- 2020
- By:
- Publication type:
- journal article
Antiretroviral drug reduction in highly experienced HIV-infected patients receiving a multidrug regimen: the ECOVIR study.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Piloting a surveillance system for HIV drug resistance in the European Union.
- Published in:
- Eurosurveillance (15607917), 2019, v. 24, n. 19, p. 1, doi. 10.2807/1560-7917.ES.2019.24.19.1800390
- By:
- Publication type:
- Article
Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS‐163 ETRAL Study
- Published in:
- Pharmacotherapy, 2019, v. 39, n. 4, p. 514, doi. 10.1002/phar.2242
- By:
- Publication type:
- Article
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study
- Published in:
- Clinical Infectious Diseases, 2019, v. 68, n. 4, p. 597, doi. 10.1093/cid/ciy505
- By:
- Publication type:
- Article
Silent Cerebral Small-Vessel Disease Is Twice as Prevalent in Middle-Aged Individuals With Well-Controlled, Combination Antiretroviral Therapy-Treated Human Immunodeficiency Virus (HIV) Than in HIV-Uninfected Individuals.
- Published in:
- Clinical Infectious Diseases, 2018, v. 66, n. 11, p. 1762, doi. 10.1093/cid/cix1075
- By:
- Publication type:
- Article
Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial.
- Published in:
- 2018
- By:
- Publication type:
- journal article
HIV-1-RNA in seminal plasma correlates with detection of HIV-1-DNA in semen cells, but not with CMV shedding, among MSM on successful antiretroviral regimens.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
- Published in:
- 2016
- By:
- Publication type:
- journal article
Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial).
- Published in:
- 2015
- By:
- Publication type:
- journal article
Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study.
- Published in:
- 2015
- By:
- Publication type:
- Letter to the Editor
HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line strategies.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2015, v. 70, n. 7, p. 2084, doi. 10.1093/jac/dkv049
- By:
- Publication type:
- Article
Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2014, v. 69, n. 6, p. 1648
- By:
- Publication type:
- Article
Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study.
- Published in:
- 2014
- By:
- Publication type:
- journal article
National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001–2011.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2013, v. 68, n. 11, p. 2626
- By:
- Publication type:
- Article
Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2013, v. 68, n. 6, p. 1400
- By:
- Publication type:
- Article
Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study.
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
Scoring Methods for Building Genotypic Scores: An Application to Didanosine Resistance in a Large Derivation Set.
- Published in:
- PLoS ONE, 2013, v. 8, n. 3, p. 1, doi. 10.1371/journal.pone.0059014
- By:
- Publication type:
- Article